Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on February 7, 2022, covering events occurring on February 3, 2022. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol "OCUL".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On February 3, 2022, Bruce A. Peacock notified the Company of his intention to resign as a member of the Board of Directors. His resignation is scheduled to take effect on the date of the Company's 2022 annual meeting of stockholders.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The sole purpose of this report is to disclose the departure of a director.
Investor Verification Checklist
- Verify the exact date of the 2022 annual meeting of stockholders to confirm the effective date of Bruce A. Peacock's resignation.
- Review subsequent filings to determine if a replacement director has been nominated or elected.
- Confirm whether the resignation impacts any board committees or governance policies.